Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24425052 | 0.88 | CA2 (0.39) | HSD11B1MGLLNOTUMP2RX7CA2 | |
| SCHEMBL7865346 | 0.83 | HSD11B1 (0.39) | HSD11B1NOTUMP2RX7CA2CNR2 | |
| SCHEMBL29410834 | 0.80 | ENPP2 (0.41) | HSD11B1MGLLCA2ENPP2MEN1 | |
| SCHEMBL4288 | 0.80 | ENPP2 (0.41) | HSD11B1MGLLCA2ENPP2MEN1 | |
| SCHEMBL31156210 | 0.79 | TAS2R14 (0.41) | HSD11B1MGLLNOTUMP2RX7CA2 | |
| SCHEMBL29525986 | 0.79 | MGLL (0.38) | HSD11B1MGLLNOTUMP2RX7CA2 | |
| SCHEMBL25192925 | 0.79 | MGLL (0.38) | MGLLENPP2PDK2 | |
| SCHEMBL187809 | 0.79 | CA2 (0.41) | MGLLNOTUMP2RX7CA2ENPP2 | |
| SCHEMBL29955350 | 0.79 | MGLL (0.38) | MGLLCA2ENPP2LMNA | |
| SCHEMBL29955679 | 0.79 | CA2 (0.41) | MGLLNOTUMP2RX7CA2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3673031-B1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-07-28 | — | — | EP | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2023239811-A1 | SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11834437-B2 | Organic molecules for optoelectronic devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4182313-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| EP-1206457-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2002-04-25 | — | — | US | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1173210-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1173426-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| CN-1290275-A | Catalyst and process for polymerization of cycloolefin | GOODRICH CO B F (US) | 2001-04-04 | — | — | CN | disclosed |
| WO-2001016120-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000066571-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066164-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | HSD11B1 847/4885MGLL 2812/4885NOTUM 1279/4885 |
| US-20230077225-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | HSD11B1 790/4885MGLL 2809/4885NOTUM 1167/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | HSD11B1 865/4885MGLL 1388/4885NOTUM 1085/4885 |
| US-11834437-B2 | Organic molecules for optoelectronic devices | OR10J3, OR51E2, OCIAD2 | HSD11B1 2499/4885MGLL 2625/4885NOTUM 2695/4885 |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | NR3C1, NR5A1, CNR1 | HSD11B1 125/4885MGLL 3514/4885NOTUM 1512/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | HSD11B1 596/4885MGLL 2763/4885NOTUM 1041/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | HSD11B1 790/4885MGLL 2809/4885NOTUM 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.